EXPLORE THE SCIENCE
TL;DR: A 2026 review in Journal of Neuroinflammation proposed that Alzheimer microglial dysfunction can be understood as checkpoint collapse, where failed regulatory controls feed three interacting lipid, iron/ferroptosis, and inflammation/complement axes. Key…
Read article
TL;DR: A 2026 preprint in medRxiv reported that people living with dementia (PLwD) and carers were generally open to artificial intelligence (AI) support in structured medication reviews, but only when AI remained validated, transparent, secure, and subordinat…
Read article
TL;DR: A 2026 Nature Communications paper introduced EmulatRx, a multi-agent AI framework that used real-world clinical data to help design target-trial-emulation workflows for acute and chronic diseases, including Alzheimer disease and Parkinson disease examp…
Read article
TL;DR: A 2026 preprint in medRxiv analyzed plasma proteomics in Alzheimer’s disease and mild cognitive impairment and found that four continuous molecular axes described the data better than hard subtype labels. Key Findings 5,895-person AD/MCI sample: The dis…
Read article
TL;DR: A 2026 preprint in medRxiv warned that a standard Alzheimer’s disease biomarker-clock analysis can create a countdown paradox, where later biomarker-clock ages appear linked to faster mild cognitive impairment onset because of the way remaining time is…
Read article
TL;DR: A 2026 narrative review in International Journal of General Medicine argued that apathy in Alzheimer’s disease is tied to damage across motivation circuits, including the anterior cingulate cortex, orbitofrontal cortex, striatum, locus coeruleus, and la…
Read article
TL;DR: A 2026 review in International Journal of Molecular Medicine mapped how exercise and fluoxetine overlap in Alzheimer’s disease mechanisms such as mitochondrial quality control, oxidative stress, inflammation, and neuroplasticity, but clinical combinatio…
Read article
TL;DR: A 2026 systematic review and meta-analysis in Journal of Alzheimer’s Disease found that choroid plexus volume, an MRI-visible structure involved in cerebrospinal-fluid regulation and immune signaling, was larger in Alzheimer’s disease than in healthy co…
Read article
TL;DR: A 2026 real-world cohort study in The Journal of Prevention of Alzheimer’s Disease found that lecanemab-treated Alzheimer’s patients had lower Neuropsychiatric Inventory scores over follow-up, and 6-month symptom reductions were associated with regional…
Read article
TL;DR: A 2026 narrative review in Molecular Psychiatry argues that depression in Alzheimer’s disease and Parkinson’s disease follows disease-specific brain mechanisms, while standard antidepressant evidence remains weak in these neurodegenerative populations.…
Read article